PL430029A1 - Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu - Google Patents

Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu

Info

Publication number
PL430029A1
PL430029A1 PL430029A PL43002917A PL430029A1 PL 430029 A1 PL430029 A1 PL 430029A1 PL 430029 A PL430029 A PL 430029A PL 43002917 A PL43002917 A PL 43002917A PL 430029 A1 PL430029 A1 PL 430029A1
Authority
PL
Poland
Prior art keywords
escin
subject
present
acetaldehyde toxicity
extract
Prior art date
Application number
PL430029A
Other languages
English (en)
Inventor
Katarzyna KOZIAK
Original Assignee
Escilab Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escilab Spółka Z Ograniczoną Odpowiedzialnością filed Critical Escilab Spółka Z Ograniczoną Odpowiedzialnością
Publication of PL430029A1 publication Critical patent/PL430029A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Przedmiotem zgłoszenia jest płynna kompozycja do podawania doustnego zawierająca saponinę i ekstrakt z owoców aronii, znamienna tym, że saponiną jest ß-escyna, obecna w kompozycji w stężeniu od 20 do 80 mg/l, a ekstrakt z owoców aronii jest obecny w ilości wystarczającej do maskowania 10 smaku ß-escyny do stosowania w leczeniu i/lub zapobieganiu stanom metabolicznym związanym ze zwiększoną toksycznością aldehydu octowego. Przedmiotem zgłoszenia jest, ponadto, sposób leczenia i/lub zapobiegania stanom metabolicznym związanym ze zwiększoną toksycznością aldehydu octowego wynikającym z niedostatecznej aktywności enzymu dehydrogenazy aldehydowej (ALDH) u osobnika, obejmujący doustne podawanie temu osobnikowi płynnej kompozycji zawierającej ß-escynę i ekstrakt z owoców aronii, przy czym 20 stężenie ß-escyny wynosi od 20 do 80 mg/l, a ekstrakt z owoców aronii jest obecny w ilości wystarczającej do zamaskowania smaku ß-escyny.
PL430029A 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu PL430029A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619846.7A GB201619846D0 (en) 2016-11-24 2016-11-24 Saponin composition
PCT/IB2017/057395 WO2018096502A1 (en) 2016-11-24 2017-11-24 Oral compositions comprising beta-escin for reducing acetaldehyde toxicity

Publications (1)

Publication Number Publication Date
PL430029A1 true PL430029A1 (pl) 2021-03-08

Family

ID=58073282

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17812273.5T PL3544615T3 (pl) 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę i sok z aronii do obniżania toksyczności aldehydu octowego
PL430029A PL430029A1 (pl) 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17812273.5T PL3544615T3 (pl) 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę i sok z aronii do obniżania toksyczności aldehydu octowego

Country Status (8)

Country Link
US (1) US10799550B2 (pl)
EP (1) EP3544615B1 (pl)
JP (1) JP7070933B2 (pl)
KR (1) KR102569055B1 (pl)
AU (1) AU2017365116B2 (pl)
GB (1) GB201619846D0 (pl)
PL (2) PL3544615T3 (pl)
WO (1) WO2018096502A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062312A1 (en) * 2018-10-05 2022-03-03 Escilab Sp Z O. O. Oral composition comprising b-escin and the use thereof
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3533231B2 (ja) * 1993-08-20 2004-05-31 森下仁丹株式会社 アルコール吸収抑制剤
JP4777495B2 (ja) * 1999-04-01 2011-09-21 森下仁丹株式会社 アルコール障害予防剤およびそれを含有する食品
EP1976391B1 (en) * 2005-12-30 2010-10-20 Cadbury Holdings Limited Chewing gum composition containing chokeberry
KR101383276B1 (ko) * 2012-03-05 2014-04-08 염장열 아로니아 음료 농축액 및 그 제조방법
KR20140090453A (ko) * 2013-01-09 2014-07-17 (주) 제이비케이자연의학연구소 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
PL405318A1 (pl) * 2013-09-11 2015-03-16 Cezary Bilski Preparat złożony wspomagający odchudzanie na bazie wyciągów roślinnych
KR20160100572A (ko) * 2015-02-16 2016-08-24 학교법인연세대학교 고미가 제거된 남가새 음료 및 이의 제조방법
EP3078381A1 (en) * 2015-04-10 2016-10-12 Warszawski Uniwersytet Medyczny Horse chestnut extract or escins for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
KR102569055B1 (ko) 2023-08-21
US20190321432A1 (en) 2019-10-24
AU2017365116B2 (en) 2023-06-22
WO2018096502A1 (en) 2018-05-31
KR20190087437A (ko) 2019-07-24
JP2019535779A (ja) 2019-12-12
AU2017365116A1 (en) 2019-05-23
US10799550B2 (en) 2020-10-13
GB201619846D0 (en) 2017-01-11
PL3544615T3 (pl) 2022-09-19
EP3544615A1 (en) 2019-10-02
JP7070933B2 (ja) 2022-05-18
EP3544615B1 (en) 2022-05-18
CA3044504A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
PH12017502092A1 (en) Topical pharmaceutical compositions
WO2007081773A3 (en) Treatment of fatty liver
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
MY209059A (en) Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
MX2022015799A (es) Composicion y metodo para el tratamiento del dolor cronico.
WO2018025080A3 (en) Compositions for enhancing brain activity
HRP20160406T1 (hr) Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima
UA90668C2 (ru) Состав для лечения хронической венозной недостаточности, который содержит водный экстракт листьев красного винограда и противовоспалительное средство
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
MX342703B (es) Enmascaramiento del amargor.
RU2019105734A (ru) Фармацевтическая композиция для применения при лечении патологий простаты
MEP7809A (en) Use of docetaxel for treating hepatocellular carcinoma
NO20075945L (no) Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav
MY197721A (en) Composition and uses thereof
HRP20211488T1 (hr) Sastav i metoda za liječenje metaboličkih poremećaja
CN106265633A (zh) Nrf2激活子化合物、药物及白术内酯ⅱ的新用途
MX2023000899A (es) Administracion de beta-hidroxibutirato y compuestos relacionados en humanos para el tratamiento y/o prevencion de enfermedades respiratorias.
TW201511766A (zh) 用於增進男性性健康之方法及組合物
NZ733658A (en) Compositions and methods for chronic use of a weight-gaining compound
PL423673A1 (pl) Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
PH12022553179A1 (en) A pharmarceutical composition capable of inhibiting replication of coronavirus
JP2019535779A5 (pl)
FI20135503A7 (fi) Kysteiini tai sen johdannainen atrofisen gastriitin hoitamiseen